Mus musculus
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA137041 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:This laboratory focuses on selectin mediated recruitment during adoptive immunotherapy for metastatic cancer. This study seeks to determine changes in the expression levels of Fucosyltransferases, Selectins, and cytokines in normal and inflamed mouse skin, melanoma tumor tissue of different sizes, and tumor cells grown in culture. Since the ability to treat the tumor effectively is directly related to the size of the tumor, differences in glyco-expression patterns may be of interest. In this study, five groups were hybridized and analyzed using the GLYCOv2 array. Each group was analyzed in triplicate. The groups were: Normal mouse skin, normal mouse skin inflamed by treatment with Oxazolone, B16-OVA melanoma tissue from 6 day tumors, B16-OVA melanoma tissue from 11 day tumors, and B16-OVA grown in cell culture.
2011-02-17 | E-GEOD-27355 | biostudies-arrayexpress
Project description:Gene expression analysis of B16-F1 melanoma tumors established in WT and Stat2KO mice
| PRJNA244616 | ENA
Project description:Adoptive T-cell therapy has shown promising results with high response rates and frequent complete responses in B-cell malignancies, offering hope for its application to a broad spectrum of cancers. However, a significant portion of patients with solid tumors experience primary or secondary resistance to this treatment modality. Known resistance mechanisms to this therapy include tumor heterogeneity and target antigen loss resulting from defects in antigen processing and presentation machinery. Constitutively expressed membrane-anchored interleukin-12 (caIL-12) has demonstrated low systemic exposure and antitumor activity in multiple preclinical adoptive T-cell treatment models. In this study, we assess the therapeutic impact of caIL-12 on target antigen-negative variants within a heterogeneous tumor. Target antigen-positive tumors were generated by engineering OVA-SIINFEKL peptide to B16 melanoma (B16-U-OVA), while B16 tumors served as antigen-negative variants. C57BL mice bearing heterogeneous tumors were treated with OT-I TCR-T cells engineered with or without caIL-12. Our results demonstrated that TCR-T cells (OT-I) could effectively deliver caIL-12 to the B16-U-OVA tumor sites and induce robust tumor control and survival benefits even in mice bearing OVA-negative B16 tumor variants. CaIL-12 was found to exert its effect on OVA-negative B16 variants within heterogeneous tumors primarily by activating endogenous antitumor CD8 T cells via antigen spreading. In addition, antigen spreading induced by OT-I-ca12 resulted in controlling OVA-negative tumors implanted at distant sites. This therapeutic effect required antigen-specific TCR-T cells and caIL-12 to co-localize at the tumor site, along with endogenous CD8 T cells capable of recognizing shared tumor antigens. These findings highlight the potential of caIL-12 to address challenges of antigen escape and tumor heterogeneity that may limit the efficacy of T-cell therapy against solid tumors.
2025-10-31 | GSE277398 | GEO
Project description:Treg cell gene expression signature in B16 melanoma
| PRJNA344445 | ENA
Project description:Melan-a mouse melanocytes vs. B16 mouse melanoma cells
| PRJNA109149 | ENA
Project description:Role of SOCS1 inactivation on OT1 transferred T cells anti-tumor activity in B16-OVA melanoma tumoirs
2021-09-02 | GSE154792 | GEO
Project description:Compared to CAR.CD19 T cells, we found that CAR.CD19 NKTs showed superior control of tumor growth in the B16-OVA-hCD19 melanoma model without evident toxicity. To investigate whetehr CAR.CD19 NKTs could affect the TME in the tumor. We used the single RNA seq to test the TME cell populations in the B16-OVA-hCD19 model between CAR.CD19 NKTs and CAR.CD19 Ts.
2024-08-21 | GSE236066 | GEO
Project description:Time course RA-treatment of B16 mouse melanoma cells
| PRJNA109147 | ENA
Project description:We previously showed that transgenic enhancement of histamine production in B16-F10 melanomas strongly supports tumor growth in C57Bl/6 mice (Cancer Res, 2005 Pos et al.). In this array experiment, gene expression profiles of transgenic mouse melanomas, secreting different amounts of histamine, were compared by whole genome microarrays. Experiment Overall Design: By modifying the levels of L-histidine decarboxylase (HDC), the sole enzyme responsible for histamine production, we introduced three novel variants of the B16-F10 mouse melanoma cell line, displaying diminished (B16-F10 HDC-A), unmodified (B16-F10 HDC-M) or enhanced (B16-F10 HDC-S) capacities to produce and secrete histamine. Experiment Overall Design: In this experiment, B16-F10 HDC-A, HDC-M, and HDC-S experimental mouse melanomas were compared by analyzing 6-6 tumors in each group. Experiment Overall Design: In order to reduce the amount of arrays required, equal amounts of randomly chosen RNA sample pairs were pooled in each group, thus, at the end, each group consisted of 3 pooled tumor samples. All samples were biological replicates, no technical replicates or dye swapping were done. Experiment Overall Design: Gene expression patterns of the three tumor groups were compared indirectly, via a common reference samplei n a two-color array design. Arrays shown here represent gene expression patterns of individual tumor samples compared to the reference sample.
2008-06-16 | E-GEOD-8541 | biostudies-arrayexpress
Project description:This study investigated how the depletion of natural killer (NK) cells in mice treated with a combined PD-1/CTLA-4 blockade affects the molecular profiles of intracranial tumors in a two-site B16-OVA melanoma brain metastases model. This model contains concomitant intracranial and extracranial tumors, to mimic the presence of extracranial metastases in melanoma patients with brain metastases, and intracranial responses to the combined PD-1/CTLA-4 blockade that are observed in the clinic can be reproduced in this model.
2024-08-29 | GSE264376 | GEO